GoodRx restates Q1 and Q2 2026 results, raising six-month revenue by $29.8 million
GoodRx said its financial statements for the quarters ended March 31 and June 30, 2026 should no longer be relied upon because Pharma Direct revenue was understated, and that prior reports on those periods should also not be relied upon. The corrected figures are higher, but the company expects to report material weaknesses in internal control over financial reporting, and the restatement remains preliminary.
Key points
- Six-month total revenue to June 30, 2026 would rise from $394.4 million to $424.2 million.
- Six-month net income would rise from $9.7 million to $24.6 million, and diluted EPS from $0.03 to $0.07.
- The company expects to report one or more material weaknesses in internal control over financial reporting for each affected period.
- The company plans to file amended Forms 10-Q for the affected periods as soon as practicable.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.